



## Sklice® (ivermectin) – New over-the-counter approval

- On October 27, 2020, the [FDA announced](#) the [approval](#) of over-the-counter (OTC) use of Arbor Pharmaceuticals' [Sklice \(ivermectin\)](#), for treatment of head lice.
  - Previously, Sklice was available as [prescription](#) for treatment of head lice infestations in patients 6 months of age and older.
- Sklice will no longer be available as a prescription drug.
- Sklice is a single-use lotion with ivermectin 0.5% as the active ingredient. Sklice is for external use only and should only be used on the scalp and dry hair in accordance with label directions.
- Patients should stop use of OTC Sklice and ask a doctor if they experience breathing difficulty, eye irritation, skin or scalp irritation continues or infection occurs, or rash develops.
- Arbor Pharmaceuticals' launch plans for OTC Sklice are pending.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.